Out on Wall Street, one group of stocks divides investors into either fans or critics. Penny stocks, or tickers that trade for less …
Galectin Therapeutics (NASDAQ:GALT) announced positive FDA guidance from a discussion on the clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH cirrhosis. Based …
Galectin Therapeutics Inc (NASDAQ:GALT) shares are jumping almost 18% today on the heels of the drug maker walking into a credit line to …
Roth Capital’s Yasmeen Rahimi still pinpoints almost 30% upside potential for GALT shares following the biotech firm’s failed Phase 2b trial.
H.C.
Galectin Therapeutics Inc (NASDAQ:GALT) is crash-landing 35% to the market floor once investors caught word of the biotech firm’s Phase 2b NASH-CX study …
Galectin Therapeutics Inc (NASDAQ:GALT) investors are overwhelmingly excited today after the drug maker announced its plans to identify a strategic partnership for its galectin-3 …
On Tuesday, Galectin Therapeutics Inc (NASDAQ:GALT) reported that its pipeline investigational drug GR-MD-02, designed to treat liver fibrosis, missed its primary endpoint in …
Galectin Therapeutics Inc (NASDAQ:GALT) shareholders are having a rough day after the biopharmaceutical company announced disappointing topline results from NASH-FX, its Phase 2a clinical …
Galectin Therapeutics Inc (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the appointment of Adam …